Shares of Vical Incorporated (NASDAQ:VICL) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.76. Vical shares last traded at $0.74, with a volume of 742,004 shares changing hands.

Separately, Zacks Investment Research raised shares of Hallmark Financial Services from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, July 19th.

The stock has a market capitalization of $15.30 million, a PE ratio of -0.88 and a beta of 0.29. The company’s 50-day moving average is $0.81.

Vical (NASDAQ:VICL) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Vical had a negative net margin of 1,002.10% and a negative return on equity of 29.46%. As a group, research analysts expect that Vical Incorporated will post -0.36 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Vical stock. Acadian Asset Management LLC lifted its stake in shares of Vical Incorporated (NASDAQ:VICL) by 23.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 219,221 shares of the biotechnology company’s stock after acquiring an additional 41,036 shares during the quarter. Acadian Asset Management LLC owned 1.00% of Vical worth $263,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 33.75% of the company’s stock.

Vical Company Profile (NASDAQ:VICL)

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Featured Story: Analyst Ratings Trading

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with's FREE daily email newsletter.